Meningococcal Vaccine Market: Global Industry Research Report 2020-2027 | Envisage Research

Meningococcal Vaccine Market - By Types (quadrivalent, bivalent, serogroup A, serogroup B and serogroup X), By End-Users (Children, Teens and Adults), By Composition (Mono Vaccines, Combination Vaccines), By Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Analysis, opportunity and Forecast 2020 To 2027

Published Date: May 2021

No. of Pages: 201

Status: Published

Report Code: EMR100346

The Global meningococcal vaccine market is expected to be worth $XX bn by 2030. Meningococcal vaccine is used to prevent contagious infection of the membranes that surround the brain and spinal cord caused by Neisseria meningitides. Three types of vaccines are present to act against meningococcal disease which target serogroups A, C, W-135, and Y of meningococcus. These vaccines are mainly used to immunize infants and children against invasive diseases caused by Neisseria meningitides.
The major factors that contribute to the growth of the meningococcal conjugate vaccine market include increasing prevalence of diseases caused by microorganisms such as Neisseria meningitides, improving healthcare infrastructure, development of quality vaccines at an affordable price, and growing awareness about meningococcal vaccination & associated immunization. However, high costs, adverse effects of vaccines, and stringent government regulations hamper the growth of the global meningococcal conjugate vaccine market. Development of combination vaccines and large numbers of mergers & acquisition strategies among key vendors are expected to propel the growth of the market in the near future.

The leading players operating in the global meningococcal vaccines market. They include Baxter International, Sanofi SA, Novartis International, JN-International Medical Corporation, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, Serum Institute of India Ltd., and Biomed Pvt. Ltd. Increase in mergers & acquisitions, strategic collaborations, and new product launches are expected to drive the global market during the forecast period.

Analyst Commentary

The growth of market will continue to be largely impacted by high adoption rate among young adults. In light of the growing awareness about new vaccines for treating meningococcal meningitis increasing number of ongoing clinical programs for meningococcal vaccines across the globe, at different stages of development holds significant gains for the market players. The companies focusing on evaluating potential of existing meningococcal vaccines for use in expanded age indication are envisaged to reinforce their foothold in the meningococcal vaccine market through 2029.
Several vaccine manufacturers are shifting their bases to developing countries to utilize the favourable business environment in these countries. The global players are targeting countries like India and China as vaccine development hubs because of the availability of skilled manpower, excellent manufacturing capabilities, and low-manufacturing costs. So, it can be clearly said that this market has got a huge scope.

When it comes to bifurcation by composition mono vaccine has got an upper hand, the reason being that these vaccines provide protection against single or multiple serogroups of disease-causing organisms, such as Neisseria meningitides, which are responsible for meningococcal diseases. These vaccines are further segmented into polysaccharide and conjugate vaccines. Growing incidences of meningococcal diseases across the globe will lead to this segment’s growth during the forecast period.

Segmentation

The meningococcal vaccine market can be classified based on its types into quadrivalent, bivalent, serogroup A, serogroup B and serogroup X. Polysaccharide and conjugate are two types of quadrivalent vaccine. A new vaccine named Baxsero, a conjugate vaccine has been a huge success in prevention of meningitis. Another mode of bifurcation would be on the basis of application or end users which are children, teens and adults. And when it comes to segmentation on the basis of composition, it can be bifurcated into 2 parts mono vaccines, combination vaccines.

Regional analysis

North America is expected to be a highly lucrative market for meningococcal vaccines during the forecast period. The region held major share of the global meningococcal vaccines market due to high rate of adoption of advanced products and rise in penetration of new entrants with novel technology. The U.S. held a major share of the market in North America as well as globally. The country is a major innovation hub, where the world’s leading companies conduct research and development.
In terms of region, the global meningitis vaccine market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global meningitis vaccine market. The region is projected to account for a significant share of the global meningitis vaccine market during the forecast period due to presence of key vaccine manufacturers and awareness about immunization

TABLE OF CONTENTS
Chapter 1. Executive Summary
Chapter 2. Research Methodology
2.1. Research approach
2.2. Scope, definition, and assumptions
2.3. Data sources
2.3.1. Secondary Sources
2.3.1.1. Preliminary data mining
2.3.2. Primary Sources
2.3.2.1. Statistical Model
2.3.2.2. Data Triangulation
2.3.2.3. Research Objective
Chapter 3. Market Outlook
3.1. Introduction
3.2. Key trends
3.2.1. xx
3.3. Market drivers
3.3.1. Impact analysis of Market Drivers
3.4. Market restraints
3.4.1. Impact analysis of Market Restraints
3.5. Market opportunities
3.5.1. Impact analysis of Market Opportunities
3.6. Market Challenges
3.6.1. Impact analysis of Market Trends
3.7. Porter’s Five Forces’ analysis
3.7.1. Bargaining Power of Suppliers
3.7.2. Bargaining Power of Buyers
3.7.3. Threat of New Entrant
3.7.4. Threat of Substitutes
3.7.5. High Competitive Rivalry
3.8. Value chain analysis
Chapter 4. COVID-19 Impact On Meningococcal Market
Chapter 5. Global Meningococcal Market Overview, By Type, 2015 - 2027 (Kilo Tons) (USD Million)
5.1. Global Meningococcal Market Share, By Type, 2015 - 2027 (USD Million)
5.1.1. Serogroup A
5.1.1.1. Market Size and Projections,2015 - 2027 (USD Million)
5.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.2. Serogroup B
5.1.2.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.2.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.3. Serogroup X
5.1.3.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.3.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.4. Bivalent Vaccines
5.1.4.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.4.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
5.1.5. Quadrivalent Vaccines
5.1.5.1. Market Size and Projections, 2015 - 2027 (USD Million)
5.1.5.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 6. Meningococcal Market Overview, By End User, 2015 - 2027 (Kilo Tons) (USD Million)
6.1. Meningococcal Share, By End User, 2015 - 2027 (USD Million)
6.1.1. Children
6.1.1.1. Market Size and projections,2015 - 2027 (Kilo Tons) (USD Million)
6.1.1.2. Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.2. Teenagers
6.1.2.1. Market Size and projections,2015 – 2027 (USD Million)
6.1.2.2. Market Size and Projections, by Region, 2015 - 2027 Market Size and Projections, by Region, 2015 - 2027 (USD Million)
6.1.3. Adults
6.1.3.1. Market Size and projections,2015 – 2027 (USD Million)
6.1.3.2. Market Size and Projections, by Region, 2015 - 2027 Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 7. Meningococcal Market Overview, By Composition, 2015 - 2027 (Kilo Tons) (USD Million)
7.1. Meningococcal Share, By Composition, 2015 - 2027 (USD Million)
7.1.1. Mono Vaccine
7.1.1.1. Market Size and projections,2015 – 2027 (USD Million)
7.1.1.2. Market Size and Projections, by Region, 2015 - 2027 Market Size and Projections, by Region, 2015 - 2027 (USD Million)
7.1.2. Combination Vaccine
7.1.2.1. Market Size and projections,2015 – 2027 (USD Million)
7.1.2.2. Market Size and Projections, by Region, 2015 - 2027 Market Size and Projections, by Region, 2015 - 2027 (USD Million)
Chapter 8. Meningococcal Market Overview, By Geography, 2015 - 2027 (Kilo Tons) (USD Million)
8.1. Meningococcal Market Share, By Geography, 2015 - 2027 (Kilo Tons) (USD Million)
8.1.1. Market Size and projections, by Countries, 2015 – 2027 (USD Million)
8.1.2. Market Share and CAGR Comparison, by Countries, 2019 (%)
Chapter 9. North America Meningococcal Market Overview, By Countries, 2015 - 2027 (Kilo Tons) (USD Million)
9.1. North America Meningococcal Market Overview, 2015 - 2027 (USD Million)
9.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.2. North America Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.3. North America Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
9.1.4. North America Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
9.1.5. North America Meningococcal Market Overview, By Countries, 2015 - 2027 (USD Million)
9.1.5.1. U.S. Meningococcal Market Overview, 2015 - 2027 (USD Million)
9.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.5.1.2. U.S. Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.5.1.3. U.S. Meningococcal Market Overview, By End User,2015 - 2027 (USD Million)
9.1.5.1.4. U.S. Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
9.1.5.2. Canada Meningococcal Market Overview, 2015 - 2027 (Kilo Tons) (USD Million)
9.1.5.2.1. Market size and projections, 2015 - 2027 (Kilo Tons) (USD Million)
9.1.5.2.2. Canada Meningococcal Market Overview, By Type, 2015 – 2027 (USD Million)
9.1.5.2.3. Canada Meningococcal Market Overview, By End User,2015 - 2027 (USD Million)
9.1.5.2.4. Canada Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
9.1.5.3. Mexico Meningococcal Market Overview, 2015 - 2027 (USD Million)
9.1.5.3.1. Market size and projections, 2015 - 2027 (USD Million)
9.1.5.3.2. Mexico Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
9.1.5.3.3. Mexico Meningococcal Market Overview, By End User,2015 - 2027 (USD Million)
9.1.5.3.4. Mexico Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
Chapter 10. Europe Meningococcal Market Overview, By Countries, 2015 - 2027 (Kilo Tons) (USD Million)
10.1. Europe Meningococcal Market Overview, 2015 – 2027 (USD Million)
10.1.1. Market size and projections, 2015 - 2027 (Kilo Tons) (USD Million)
10.1.2. Europe Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.3. Europe Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.4. Europe Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
10.1.5. Europe Meningococcal Market Overview, By Countries, 2015 - 2027 (USD Million)
10.1.5.1. Germany
10.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.1.2. Germany Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.1.3. Germany Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.1.4. Germany Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
10.1.5.2. France
10.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.2.2. France Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.2.3. France Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.2.4. France Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
10.1.5.3. UK
10.1.5.3.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.3.2. UK Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.3.3. UK Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.3.4. UK Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
10.1.5.4. Italy
10.1.5.4.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.4.2. Italy Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.4.3. Italy Meningococcal Market Overview, By End User 2015 - 2027 (USD Million)
10.1.5.4.4. Italy Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
10.1.5.5. Spain
10.1.5.5.1. Market size and projections, 2015 - 2027 (USD Million)
10.1.5.5.2. Spain Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.5.3. Spain Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.5.4. Spain Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
10.1.5.6. Rest of Europe
10.1.5.6.1. Market size and projections, 2015 – 2025
10.1.5.6.2. Rest of Europe Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
10.1.5.6.3. Rest of Europe Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
10.1.5.6.4. Rest of Europe Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
Chapter 11. Asia Pacific Meningococcal Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1. Asia Pacific Meningococcal Market Overview, 2015 - 2027 (USD Million)
11.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.2. Asia Pacific Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.3. Asia Pacific Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.4. Asia Pacific Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
11.1.5. Asia Pacific Meningococcal Market Overview, By Countries, 2015 - 2027 (USD Million)
11.1.5.1. India
11.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.1.2. India Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.1.3. India Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.1.4. India Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
11.1.5.2. China
11.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.2.2. China Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.2.3. China Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.2.4. China Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
11.1.5.3. Japan
11.1.5.3.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.3.2. Japan Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.3.3. Japan Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.3.4. Japan Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
11.1.5.4. South Korea
11.1.5.4.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.4.2. South Korea Meningococcal Market Overview, By Type, 2015 - 2027 (Kilo Tons) (USD Million)
11.1.5.4.3. South Korea Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.4.4. South Korea Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
11.1.5.5. Rest of Asia Pacific
11.1.5.5.1. Market size and projections, 2015 - 2027 (USD Million)
11.1.5.5.2. Rest of Asia Pacific Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
11.1.5.5.3. Rest of Asia Pacific Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
11.1.5.5.4. Rest of Asia Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
Chapter 12. Middle East & Africa Meningococcal Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1. Middle East & Africa Meningococcal Market Overview, 2015 - 2027 (USD Million)
12.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.2. Middle East & Africa Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.3. Middle East & Africa Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.4. Middle East & Africa Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
12.1.5. Middle East & Africa Meningococcal Market Overview, By Countries, 2015 - 2027 (USD Million)
12.1.5.1. GCC
12.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.5.1.2. GCC Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.1.3. GCC Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.5.1.4. GCC Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
12.1.5.2. South Africa
12.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.5.2.2. South Africa Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.2.3. South Africa Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.5.2.4. South Africa Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
12.1.5.3. Rest of Middle East & Africa
12.1.5.3.1. Market size and projections, 2015 - 2027 (USD Million)
12.1.5.3.2. Rest of Middle East & Africa Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
12.1.5.3.3. Rest of Middle East & Africa Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
12.1.5.3.4. Rest of Middle East Africa Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
Chapter 13. South America Meningococcal Market Overview, By Countries, 2015 - 2027 (USD Million)
13.1. South America Meningococcal Market Overview, 2015 - 2027 (USD Million)
13.1.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.2. South America Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.3. South America Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.4. South America Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
13.1.5. South America Meningococcal Market Overview, By Countries, 2015- 2026 (USD Million)
13.1.5.1. Brazil
13.1.5.1.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.5.1.2. Brazil Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.5.1.3. Brazil Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.5.1.4. Brazil Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
13.1.5.2. Argentina
13.1.5.2.1. Market size and projections, 2015 - 2027 (USD Million)
13.1.5.2.2. Argentina Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.5.2.3. Argentina Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.5.2.4. Argentina Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
13.1.5.3. Rest of South America
13.1.5.3.1. Market size and projections, 2015 – 2026
13.1.5.3.2. Rest of South America Meningococcal Market Overview, By Type, 2015 - 2027 (USD Million)
13.1.5.3.3. Rest of South America Meningococcal Market Overview, By End User, 2015 - 2027 (USD Million)
13.1.5.3.4. Rest of South America Meningococcal Market Overview, By Composition, 2015 - 2027 (USD Million)
Chapter 14. Competitive Landscape
14.1. Competitive environment, 2020
14.2. Strategic framework
14.2.1. Partnership/agreement
14.2.2. Expansion
14.2.3. Mergers & Acquisitions
14.2.4. New Type development
Chapter 15. Key Vendor Analysis
15.1. Baxter International.
15.1.1. Company overview
15.1.2. Financial performance
15.1.3. Type Benchmarking
15.1.4. Recent initiatives
15.1.5. SWOT analysis
15.2. Sanofi SA.
15.2.1. Company overview
15.2.2. Financial performance
15.2.3. Type Benchmarking
15.2.4. Recent initiatives
15.2.5. SWOT analysis
15.3. JN International Medical Corporation
15.4. Sanofi SA.
15.5. Glaxo Smith Kline plc.
15.6. Biomed Pvt. Ltd
15.7. Serum Institute of India Ltd
15.8. Pfizer Inc
15.9. Nuron Biotech
15.10. Novartis International
Chapter 16. Meningococcal Market Cost Analysis
16.1. Meningococcal Market Key Raw Materials Analysis
16.1.1. Key Raw Materials
16.1.2. Price Trend of Key Raw Materials
16.1.3. Key Suppliers of Raw Materials
16.1.4. Market Concentration Rate of Raw Materials
16.2. Proportion of Wing Cost Structure
16.2.1. Raw Materials
16.2.2. Labor Cost
16.2.3. Wing Expenses
16.3. Wing Process Analysis of Unsaturated Polyester Resin (UPR) for Composites
Chapter 17. Chain, Sourcing Strategy and Downstream Buyers
17.1. Meningococcal Market Chain Analysis
17.2. Upstream Raw Materials Sourcing
17.3. Raw Materials Sources of Meningococcal Market Major Manufacturers in 2019
17.4. Downstream Buyers
Chapter 18. Marketing Strategy Analysis, Distributors/Traders
18.1. Marketing Channel
18.1.1. Direct Marketing
18.1.2. Indirect Marketing
18.1.3. Marketing Channel Development Trend
18.2. Market Positioning
18.2.1. Pricing Strategy
18.2.2. Brand Strategy
18.2.3. Target Teenagers
18.3. Distributors/Traders List
Chapter 19. Market Effect Factors Analysis
19.1. Type Progress/Risk
19.1.1. Substitutes Threat
19.1.2. Type Progress in Related Industry
19.2. Consumer Needs/Customer Preference Change
19.3. Economic/Political Environmental Change
Chapter 20. Future Outlook of the Market
Disclaimer

List of Figures
1. Market segmentation
2. Value chain analysis
3. Porter’s Five Forces’ analysis
4. Power of Suppliers
5. Power of Buyers
6. Threat of New Entrants
7. Threat of Substitute
8. Competitive Rivalry
9. Global Meningococcal Market share, by Type, 2020 & 2027 (%)
10. Global Meningococcal Market share, by Type 2020 & 2027 (USD Million)
11. Global Meningococcal market share, by Serogroup A, by Type, 2020 & 2027 (USD Million)
12. Global Meningococcal market share, by Serogroup B, by Type, 2020 & 2027 (USD Million)
13. Global Meningococcal market share, by Serogroup X, by Type, 2020 & 2027 (USD Million)
14. Global Meningococcal market share, by Bivalent Vaccines, by Type, 2020 & 2027 (USD Million)
15. Global Meningococcal market share, by Quadrivalent Vaccines, by Type, 2020 & 2027 (USD Million)
16. Global Meningococcal Market share, by End User, 2020 & 2027 (%)
17. Global Meningococcal market share, by Children, by End User, 2020 & 2027 (USD Million)
18. Global Meningococcal market share, by Teenagers, by End User, 2020 & 2027 (USD Million)
19. Global Meningococcal market share, by Adults, by End User, 2020 & 2027 (USD Million)
20. Global Meningococcal Market share, by Composition, 2020 & 2027 (%)
21. Global Meningococcal market share, by Mono Vaccine, by Composition, 2020 & 2027 (USD Million)
22. Global Meningococcal market share, by Combination Vaccine, by Composition, 2020 & 2027 (USD Million)
23. Global Meningococcal market share, by region, 2020 - 2027(%)
24. Global Meningococcal market share, by region, 2019 - 2027(USD Million)
25. North America Meningococcal Market, 2020 - 2027(USD Million)
26. North America Meningococcal Market share, by Countries, 2020 & 2027 (%)
27. U.S. Meningococcal Market, 2020 - 2027(USD Million)
28. Canada Meningococcal Market, 2020 - 2027(USD Million)
29. Europe Meningococcal Market, 2020 - 2027(USD Million)
30. Europe Meningococcal Market share, by Countries, 2020 & 2027 (%)
31. Spain Meningococcal Market, 2020 - 2027(USD Million)
32. UK Meningococcal Market, 2020 - 2027(USD Million)
33. Italy Meningococcal Market, 2020 - 2027(USD Million)
34. Germany Meningococcal Market, 2020 - 2027(USD Million)
35. France Meningococcal Market, 2020 - 2027(USD Million)
36. Rest of Europe Meningococcal Market, 2020 - 2027(USD Million)
37. Asia-Pacific Meningococcal Market, 2020 - 2027(USD Million)
38. Asia-Pacific Meningococcal Market share, by Countries, 2020 & 2027 (%) China Meningococcal Market, 2020 - 2027(USD Million)
39. India Meningococcal Market, 2020 - 2027(USD Million)
40. Australia Meningococcal Market, 2020 - 2027(USD Million)
41. Japan Meningococcal Market, 2020 - 2027(USD Million)
42. Rest of Asia-Pacific Meningococcal Market, 2020 - 2027(USD Million)
43. Middle East & Africa Meningococcal Market, 2020 - 2027(USD Million)
44. Middle East & Africa Meningococcal Market share, by Countries, 2020 & 2027 (%)
45. GCC Meningococcal Market, 2020 - 2027(USD Million)
46. South Africa Meningococcal Market, 2020 - 2027(USD Million)
47. Rest Of Middle East & Africa Meningococcal Market, 2020 - 2027(USD Million)
48. South America Meningococcal Market, 2020 - 2027(USD Million)
49. Brazil Meningococcal Market, 2020 - 2027(USD Million)
50. Mexico Meningococcal Market, 2020 - 2027(USD Million)
51. Argentina Meningococcal Market, 2020 - 2027(USD Million)
52. Rest Of South America Meningococcal Market, 2020 - 2027(USD Million)

List of Tables

1. Impact of Market drivers
2. Impact of Market restraints
3. Global Meningococcal Market, 2020-2027 (USD Million)
4. Meningococcal requirement, by country, 2020-2027, (USD Million)
5. North America Meningococcal Market, by Type, 2020-2027 (USD Million)
6. North America Meningococcal Market, by End User, 2020-2027 (USD Million)
7. North America Meningococcal Market, by Composition, 2020-2027 (USD Million)
8. Europe Meningococcal Market, by Type, 2020-2027 (USD Million)
9. Europe Meningococcal Market, by End User, 2020-2027 (USD Million)
10. Europe Meningococcal Market, by Composition, 2020-2027 (USD Million)
11. Asia Pacific Meningococcal Market, by Type, 2020-2027 (USD Million)
12. Asia Pacific Meningococcal Market, by End User, 2020-2027 (USD Million)
13. Asia Pacific Meningococcal Market, by Composition, 2020-2027 (USD Million)
14. Middle East & Africa Meningococcal Market, by Type, 2020-2027 (USD Million)
15. Middle East & Africa Meningococcal Market, by End User, 2020-2027 (USD Million) .
16. Middle East & Africa Meningococcal Market, by Composition, 2020-2027 (USD Million)
17. South America Meningococcal Market, by Type, 2020-2027 (USD Million)
18. South America Meningococcal Market, by End User, 2020-2027 (USD Million)
19. South America Meningococcal Market, by Composition, 2020-2027 (USD Million)
20. Global Meningococcal Market, Company Market Share, 2018 (%)
21. BAXTER INTERNATIONAL: Product Benchmarking
22. BAXTER INTERNATIONAL: Financial Performance
23. Sanofi SA: Product Benchmarking
24. Sanofi SA: Financial Performance
25. Novartis International •: Product Benchmarking
26. Novartis International: Financial Performance
27. Novartis International: Product Benchmarking
28. Novartis International: Financial Performance
29. GlaxoSmithKline plc: Product Benchmarking
30. GlaxoSmithKline plc: Financial Performance
31. Nuron Biotech: Product Benchmarking
32. Nuron Biotech: Financial Performance
33. Serum Institute of India: Product Benchmarking
34. Serum Institute of India: Financial Performance
35. Serum Institute of India: Product Benchmarking
36. Serum Institute of India: Financial Performance
37. Pfizer Inc: Product Benchmarking
38. Pfizer Inc: Financial Performance

The Leading Key Players in Meningococcal Vaccine Market

Baxter International
Sanofi SA
Novartis International
JN-International Medical Corporation
GlaxoSmithKline plc
Pfizer Inc.
Nuron Biotech
Serum Institute of India Ltd.
Biomed Pvt. Ltd